{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:13:15Z","timestamp":1793261595743,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004360","name":"Swedish University of Agricultural Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004360","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Insulin dysregulation is a hallmark of equine metabolic syndrome (EMS), and in recent years, pharmacological treatment with sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have shown promise in reducing the risk of hyperinsulinemia-associated laminitis in horses diagnosed with EMS. In humans and laboratory animals, this transporter protein is responsible for the majority of renal tubular glucose reabsorption, however, the presence of this and the related sodium-dependent glucose transporter 1 (SGLT1) have not yet been studied in equine kidneys. Additionally, studies in humans and laboratory animals have documented the presence of SGLT1 and SGLT2 also in hepatic and pancreatic tissue, which may explain extra-renal treatment effects of SGLT2i. Since the specificity towards SGLT2 and SGLT1 differ between the various SGLT2i drugs currently in use in horses, investigating SGLT2 and SGLT1 protein expression in equine tissues may help understanding potential differences in treatment effect and\/or side effect profile between substances. The objective of this study was therefore to evaluate the presence of SGLT2 and SGLT1 in equine kidneys, liver and pancreas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tissue samples from ten healthy Norwegian\/Swedish Coldblood Trotters were collected. Using immunohistochemistry with antibodies raised against human SGLT1 and SGLT2, a strong SGLT2 antibody signal was present in the apical membranes of epithelial cells in the cortical labyrinth of the kidney, while SGLT1 positive cells were predominantly found in medullary rays. Both of these results concur with those in humans and rats. Using electron microscopy, ultrastructural localisation of positive SGLT2 antibody signal was confirmed to the microvilli of tubular epithelial cells. Positive SGLT2 signal was also detected in periportal hepatocytes and in cells within islet of Langerhans in the endocrine pancreas. Positive SGLT1 signal was seen in cholangiocytes in the portal areas of the liver, and in Kuppfer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study confirms presence of SGLT2 and SGLT1 in the equine kidney, localized to the proximal tubule. Also, presence of SGLT2 in the liver and pancreas, suggest that SGLT2i may have both renal and extrarenal effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-025-05173-1","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:13:53Z","timestamp":1765977233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue"],"prefix":"10.1186","volume":"22","author":[{"given":"Camilla","family":"Anger-H\u00e5\u00e5l","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrine T.","family":"Fjordbakk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Ekstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik S.","family":"Skedsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"R\u00f8rtveit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"5173_CR1","doi-asserted-by":"crossref","unstructured":"Durham AE, Frank N, McGowan CM, Menzies-Gow NJ, Roelfsema E, Vervuert I, et al. ECEIM consensus statement on equine metabolic syndrome. J Vet Intern Med. 2019;33(2):335\u201349.","DOI":"10.1111\/jvim.15423"},{"key":"5173_CR2","doi-asserted-by":"crossref","unstructured":"Frank N, Tadros EM. Insulin dysregulation. Equine Vet J. 2014;46(1):103-12.","DOI":"10.1111\/evj.12169"},{"key":"5173_CR3","doi-asserted-by":"crossref","unstructured":"Carslake HB, Pinchbeck GL, McGowan CM. Equine metabolic syndrome in UK native ponies and cobs is highly prevalent with modifiable risk factors. Equine Vet J. 2021;53(5):923\u201334.","DOI":"10.1111\/evj.13378"},{"key":"5173_CR4","unstructured":"Group EE. Recommendations for the diagnosis and management of equine metabolic syndrome (EMS). Equine Endocrinology Group; 2024."},{"key":"5173_CR5","doi-asserted-by":"crossref","unstructured":"Karikoski NP, Horn I, McGowan TW, McGowan CM. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion\/referral equine hospital. Domest Anim Endocr. 2011;41(3):111\u20137.","DOI":"10.1016\/j.domaniend.2011.05.004"},{"key":"5173_CR6","doi-asserted-by":"crossref","unstructured":"de Laat MA, McGowan CM, Sillence MN, Pollitt CC. Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses. Equine Vet J. 2010;42(2):129\u201335.","DOI":"10.2746\/042516409X475779"},{"key":"5173_CR7","doi-asserted-by":"crossref","unstructured":"Asplin KE, Sillence MN, Pollitt CC, McGowan CM. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies. Vet J. 2007;174(3):530\u20135.","DOI":"10.1016\/j.tvjl.2007.07.003"},{"key":"5173_CR8","doi-asserted-by":"crossref","unstructured":"Tinworth KD, Boston RC, Harris PA, Sillence MN, Raidal SL, Noble GK. The effect of oral metformin on insulin sensitivity in insulin-resistant ponies. Vet J. 2012;191(1):79\u201384.","DOI":"10.1016\/j.tvjl.2011.01.015"},{"key":"5173_CR9","doi-asserted-by":"crossref","unstructured":"Durham AE, Rendle DI, Newton JR. Effect of metformin on measurements of insulin sensitivity and \u03b2 cell response in 18 horses and ponies with insulin resistance. Equine Vet J. 2008;40(5):493\u2013500.","DOI":"10.2746\/042516408X273648"},{"key":"5173_CR10","doi-asserted-by":"crossref","unstructured":"Colmer SF, Adams AA, Adam E, Miller R, Stefanovski D, Kulp JC, et al. The effect of pre\u2010dosing with metformin on the insulin response to oral sugar in insulin\u2010dysregulated horses. Equine Vet J. 2024;56(2):318\u201325.","DOI":"10.1111\/evj.13979"},{"key":"5173_CR11","doi-asserted-by":"crossref","unstructured":"Rendle DI, Rutledge F, Hughes KJ, Heller J, Durham AE. Effects of metformin hydrochloride on blood glucose and insulin responses to oral dextrose in horses. Equine Vet J. 2013;45(6):751\u20134.","DOI":"10.1111\/evj.12068"},{"key":"5173_CR12","doi-asserted-by":"crossref","unstructured":"Frank N, Elliott SB, Boston RC. Effects of long-term oral administration of levothyroxine sodium on glucose dynamics in healthy adult horses. Am J Vet Res. 2008;69(1):76\u201381.","DOI":"10.2460\/ajvr.69.1.76"},{"key":"5173_CR13","doi-asserted-by":"crossref","unstructured":"Frank N, Buchanan BR, Elliott SB. Effects of long-term oral administration of levothyroxine sodium on serum thyroid hormone concentrations, clinicopathologic variables, and echocardiographic measurements in healthy adult horses. Am J Vet Res. 2008;69(1):68\u201375.","DOI":"10.2460\/ajvr.69.1.68"},{"key":"5173_CR14","doi-asserted-by":"crossref","unstructured":"Frank N, Sommardahl CS, Eiler H, Webb LL, Denhart JW, Boston RC. Effects of oral administration of levothyroxine sodium on concentrations of plasma lipids, concentration and composition of very-low-density lipoproteins, and glucose dynamics in healthy adult mares. American J Vet Res. 2005;66(6):1032\u20138.","DOI":"10.2460\/ajvr.2005.66.1032"},{"key":"5173_CR15","doi-asserted-by":"crossref","unstructured":"Sommardahl CS, Frank N, Elliott SB, Webb LL, Refsal KR, Denhart JW, et al. Effects of oral administration of levothyroxine sodium on serum concentrations of thyroid gland hormones and responses to injections of thyrotropin-releasing hormone in healthy adult mares. Am J Vet Res. 2005;66(6):1025\u201331.","DOI":"10.2460\/ajvr.2005.66.1025"},{"key":"5173_CR16","doi-asserted-by":"crossref","unstructured":"Kellon E, Gustafson K. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Vet J. 2022;12(4):511\u20138.","DOI":"10.5455\/OVJ.2022.v12.i4.14"},{"key":"5173_CR17","doi-asserted-by":"crossref","unstructured":"Lind\u00e5se S, Nostell K, Forslund A, Bergsten P, Br\u00f6jer J. Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind, study. J Vet Intern Med. 2023;37(6):2520\u20138.","DOI":"10.1111\/jvim.16906"},{"key":"5173_CR18","doi-asserted-by":"crossref","unstructured":"Meier A, de Laat M, Reiche D, Fitzgerald D, Sillence M. The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies. BMC Vet Res. 2019;15(1):65\u201310.","DOI":"10.1186\/s12917-019-1811-2"},{"key":"5173_CR19","doi-asserted-by":"crossref","unstructured":"Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018;13(9):e0203655-e.","DOI":"10.1371\/journal.pone.0203655"},{"key":"5173_CR20","doi-asserted-by":"crossref","unstructured":"Sundra T, Kelty E, Rendle D. Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series. Equine Vet Educ. 2023;35(6):311\u201320.","DOI":"10.1111\/eve.13738"},{"key":"5173_CR21","doi-asserted-by":"crossref","unstructured":"Sundra T, Rossi G, Kelty E, Lester G, Rendle D. Oral sugar test responses to ertugliflozin in ten horses with insulin dysregulation. Equine Vet Educ. 2024;36(6):317\u201324.","DOI":"10.1111\/eve.13924"},{"key":"5173_CR22","doi-asserted-by":"crossref","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. American J Physiol-Ren Physiol. 2014;306(2):F188\u2013F93.","DOI":"10.1152\/ajprenal.00518.2013"},{"key":"5173_CR23","doi-asserted-by":"crossref","unstructured":"Nakano D, Akiba J, Tsutsumi T, Kawaguchi M, Yoshida T, Koga H, et al. Hepatic expression of sodium\u2013glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Med Mol Morphol. 2022;55(4):304\u201315.","DOI":"10.1007\/s00795-022-00334-9"},{"key":"5173_CR24","doi-asserted-by":"crossref","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Th\u00e9venet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512\u20137.","DOI":"10.1038\/nm.3828"},{"key":"5173_CR25","doi-asserted-by":"crossref","unstructured":"Saponaro C, M\u00fchlemann M, Acosta-Montalvo A, Piron A, Gmyr V, Delalleau N, et al. Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets. Diabetes. 2020;69(5):902\u201314.","DOI":"10.2337\/db19-0888"},{"key":"5173_CR26","doi-asserted-by":"crossref","unstructured":"Hu Z, Liao Y, Wang J, Wen X, Shu L. Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice. Endocrine. 2021;74(3):571\u201381.","DOI":"10.1007\/s12020-021-02818-7"},{"key":"5173_CR27","doi-asserted-by":"crossref","unstructured":"Schwertheim S, Alhardan M, Manka PP, Sowa J-P, Canbay A, Schmidt HH-J, et al. Higher pNRF2, SOCS3, IRF3, and RIG1 Tissue Protein Expression in NASH Patients versus NAFL Patients: pNRF2 Expression Is Concomitantly Associated with Elevated Fasting Glucose Levels. J Personalized Med. 2023;13(7):1152.","DOI":"10.3390\/jpm13071152"},{"key":"5173_CR28","doi-asserted-by":"crossref","unstructured":"Maduni\u0107 IV, Breljak D, Karaica D, Koepsell H, Saboli\u0107 I. Expression profiling and immunolocalization of Na+-d-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats. Pfl\u00fcgers Archiv - European Journal of Physiology. 2017;469(12):1545-65.","DOI":"10.1007\/s00424-017-2056-1"},{"key":"5173_CR29","doi-asserted-by":"crossref","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, et al. Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Archiv: Eur J Physiol. 2015;467(9):1881\u201398.","DOI":"10.1007\/s00424-014-1619-7"},{"key":"5173_CR30","doi-asserted-by":"crossref","unstructured":"Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol: JASN. 2011;22(1):104\u201312.","DOI":"10.1681\/ASN.2010030246"},{"key":"5173_CR31","doi-asserted-by":"crossref","unstructured":"Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, et al. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012;302(8):C1174\u2013C88.","DOI":"10.1152\/ajpcell.00450.2011"},{"key":"5173_CR32","doi-asserted-by":"crossref","unstructured":"Balen D, Ljubojevi\u0107 M, Breljak D, Brzica H, Z\u0306lender V, Koepsell H, et al. Revised immunolocalization of the Na+-d-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol-Cell Physiol. 2008;295(2):C475\u2013C89.","DOI":"10.1152\/ajpcell.00180.2008"},{"key":"5173_CR33","doi-asserted-by":"crossref","unstructured":"Gorboulev V, Sch\u00fcrmann A, Vallon V, Kipp H, Jaschke A, Klessen D, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose dependent incretin secretion. Diabetes. 2012(1).","DOI":"10.2337\/db11-1029"},{"key":"5173_CR34","doi-asserted-by":"crossref","unstructured":"Du F, Hinke SA, Cavanaugh C, Polidori D, Wallace N, Kirchner T, et al. Potent Sodium\/Glucose Cotransporter SGLT1\/2 dual inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in Rodents. J Pharmacol Exp Ther. 2018;365(3):676\u201387.","DOI":"10.1124\/jpet.118.248575"},{"key":"5173_CR35","doi-asserted-by":"crossref","unstructured":"Kurosaki E, Ogasawara H. Ipragliflozin and other sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther. 2013;139(1):51\u20139.","DOI":"10.1016\/j.pharmthera.2013.04.003"},{"key":"5173_CR36","doi-asserted-by":"crossref","unstructured":"Dyer J, Fernandez-Castano Merediz E, Salmon KS, Proudman CJ, Edwards GB, Shirazi-Beechey SP. Molecular characterisation of carbohydrate digestion and absorption in equine small intestine. Equine Vet J. 2002;34(4):349\u201358.","DOI":"10.2746\/042516402776249209"},{"key":"5173_CR37","doi-asserted-by":"crossref","unstructured":"Dyer J, Al-Rammahi M, Waterfall L, Salmon KSH, Geor RJ, Bour\u00e9 L, et al. Adaptive response of equine intestinal Na+\/glucose co-transporter (SGLT1) to an increase in dietary soluble carbohydrate. Pfl\u00fcgers Archiv - Eur J Physiol. 2009;458(2):419\u201330.","DOI":"10.1007\/s00424-008-0620-4"},{"key":"5173_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-1-4939-9072-6_20","volume-title":"Oligodendrocytes: Methods and Protocols","author":"M-T Weil","year":"2019","unstructured":"Weil M-T, Ruhwedel T, Meschkat M, Sadowski B, M\u00f6bius W. Transmission electron microscopy of Oligodendrocytes and Myelin. In: Lyons DA, Kegel L, editors. Oligodendrocytes: methods and protocols. New York: Springer New York; 2019. pp. 343\u201375."},{"issue":"10","key":"5173_CR39","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L. Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30\u201350% of Filtered Glucose Load in Humans. Diabetes. 2013;62(10):3324\u20138.","journal-title":"Diabetes"},{"key":"5173_CR40","doi-asserted-by":"crossref","unstructured":"Norton L, Shannon CE, Fourcaudot M, Hu C, Wang N, Ren W, et al. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab. 2017;19(9):1322\u20136.","DOI":"10.1111\/dom.13003"},{"key":"5173_CR41","doi-asserted-by":"crossref","unstructured":"Guzelian P, Boyer JL. Glucose reabsorption from bile. Evidence for a biliohepatic circulation. J Clin Invest. 1974;53(2):526\u201335.","DOI":"10.1172\/JCI107586"},{"key":"5173_CR42","doi-asserted-by":"crossref","unstructured":"Olson JR, Fujimoto JM. Demonstration of a d-glucose transport system in the biliary tree of the rat by use of the segmented retrograde intrabiliary injection technique. Biochem Pharmacol. 1980;29(2):213\u20139.","DOI":"10.1016\/0006-2952(80)90331-7"},{"key":"5173_CR43","doi-asserted-by":"crossref","unstructured":"Tsutsumi Y. Pitfalls and caveats in applying chromogenic immunostaining to histopathological diagnosis. Cells. 2021;10(6).","DOI":"10.3390\/cells10061501"},{"key":"5173_CR44","doi-asserted-by":"crossref","unstructured":"Ogawa A, Kurita K, Ikezawa Y, Igarashi M, Kuzumaki T, Daimon M, et al. Functional localization of glucose transporter 2 in rat liver. J Histochem Cytochem. 1996;44(11):1231\u20136.","DOI":"10.1177\/44.11.8918897"},{"key":"5173_CR45","doi-asserted-by":"crossref","unstructured":"Berndt N, Holzh\u00fctter H-G. Dynamic metabolic zonation of the hepatic glucose metabolism is accomplished by sinusoidal plasma gradients of nutrients and hormones. Front Physiol. 2018;9:2018.","DOI":"10.3389\/fphys.2018.01786"},{"key":"5173_CR46","doi-asserted-by":"crossref","unstructured":"Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human atp-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet.2005;20(6):452\u201377.","DOI":"10.2133\/dmpk.20.452"},{"key":"5173_CR47","doi-asserted-by":"crossref","unstructured":"Zhao FQ, McFadden TB, Wall EH, Dong B, Zheng YC. Cloning and expression of bovine sodium\/glucose cotransporter SGLT2*. J Dairy Sci. 2005;88(8):2738\u201348.","DOI":"10.3168\/jds.S0022-0302(05)72953-2"},{"key":"5173_CR48","doi-asserted-by":"crossref","unstructured":"Zhao FQ, Zheng YC, Wall EH, McFadden TB. Cloning and expression of bovine sodium\/glucose cotransporters. J Dairy Sci. 2005;88(1):182\u201394.","DOI":"10.3168\/jds.S0022-0302(05)72677-1"},{"key":"5173_CR49","doi-asserted-by":"crossref","unstructured":"Wang D, Jinxian M, Lihua Z, and Zhang L. Research advances in the diagnosis and treatment of MASLD\/MASH. Ann Med. 2025;57(1):2445780.","DOI":"10.1080\/07853890.2024.2445780"},{"key":"5173_CR50","doi-asserted-by":"crossref","unstructured":"Berger C, Zdzieblo D. Glucose transporters in pancreatic islets. Pfl\u00fcgers Archiv - Eur J Physiol. 2020;472(9):1249\u201372.","DOI":"10.1007\/s00424-020-02383-4"},{"key":"5173_CR51","doi-asserted-by":"crossref","unstructured":"Steiner DJ, Abraham K, Kevin M, and Hara M. Pancreatic islet plasticity: Interspecies comparison of islet architecture and composition. Islets. 2010;2(3):135\u201345.","DOI":"10.4161\/isl.2.3.11815"},{"key":"5173_CR52","doi-asserted-by":"crossref","unstructured":"Helmstaedter V, Feurle GE, Forssmann WG. Insulin-, glucagon-, and somatostatin immunoreactive endocrine cells in the equine pancreas. Cell Tissue Res. 1976;172(4):447\u201354.","DOI":"10.1007\/BF00220331"},{"key":"5173_CR53","doi-asserted-by":"crossref","unstructured":"Forssmann A. The ultrastructure of the cell types in the endocrine pancreas of the horse. Cell Tissue Res. 1976;167(2):179\u201395.","DOI":"10.1007\/BF00224326"},{"key":"5173_CR54","doi-asserted-by":"crossref","unstructured":"Newkirk KM, Ehrensing G, Odoi A, Boston RC, Frank N. Immunohistochemical expression of insulin, glucagon, and somatostatin in pancreatic islets of horses with and without insulin resistance. American Vet Res. 2018;79(2):191\u20138.","DOI":"10.2460\/ajvr.79.2.191"},{"key":"5173_CR55","doi-asserted-by":"crossref","unstructured":"Kellon EM, Gustafson KM. Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors. Open Vet J. 2023;13(3):365\u201375.","DOI":"10.5455\/OVJ.2023.v13.i3.14"},{"key":"5173_CR56","doi-asserted-by":"crossref","unstructured":"Pedersen MG, Ahlstedt I, El Hachmane MF, G\u00f6pel SO. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016;6(1):31214.","DOI":"10.1038\/srep31214"},{"key":"5173_CR57","doi-asserted-by":"crossref","unstructured":"Chae H, Augustin R, Gatineau E, Mayoux E, Bensellam M, Antoine N, et al. SGLT2 is not expressed in pancreatic \u03b1-and \u03b2-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. Mol Metab. 2020;42:101071.","DOI":"10.1016\/j.molmet.2020.101071"},{"key":"5173_CR58","doi-asserted-by":"crossref","unstructured":"Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62(6):1011\u201323.","DOI":"10.1007\/s00125-019-4849-6"},{"key":"5173_CR59","doi-asserted-by":"crossref","unstructured":"Brown PJ, Whitbread TJ, Bell NJ, Burden FA. Haemosiderin deposition in Donkey (Equus asinus) liver: comparison of liver histopathology with liver iron content. Res Vet Sci. 2011;90(2):275\u20139.","DOI":"10.1016\/j.rvsc.2010.05.033"},{"key":"5173_CR60","doi-asserted-by":"crossref","unstructured":"Durham AE, Smith KC, Newton JR, Hillyer MH, Hillyer LL, Smith MRW, et al. Development and application of a scoring system for prognostic evaluation of equine liver biopsies. Equine Vet J. 2003;35(6):534\u201340.","DOI":"10.2746\/042516403775467171"},{"key":"5173_CR61","doi-asserted-by":"crossref","unstructured":"Theelen MJP, Beukers M, Grinwis GCM, Sloet van Oldruitenborgh\u2010Oosterbaan MM. Chronic iron overload causing haemochromatosis and hepatopathy in 21 horses and one donkey. Equine Vet J.2019;51(3):304\u20139.","DOI":"10.1111\/evj.13029"},{"key":"5173_CR62","unstructured":"Consortium TU. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res. 2025;53:D609\u2013D17."},{"key":"5173_CR63","doi-asserted-by":"crossref","unstructured":"Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Immunohistochemical localization of Na+-dependent glucose transporter in rat jejunum. Cell Tissue Res. 1992;267(1):3\u20139.","DOI":"10.1007\/BF00318685"},{"key":"5173_CR64","doi-asserted-by":"crossref","unstructured":"Chichger H, Cleasby ME, Srai SK, Unwin RJ, Debnam ES, Marks J. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane. Exp Physiol. 2016;101(6):731\u201342.","DOI":"10.1113\/EP085670"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-05173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-025-05173-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-05173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:49:01Z","timestamp":1768992541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12917-025-05173-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5173"],"URL":"https:\/\/doi.org\/10.1186\/s12917-025-05173-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance to journal policies (\n                      \n                      ) the study was reviewed by the Ethical committee for approval of studies with animal patients, an ethical committee affiliated to the Norwegian University of Life Sciences. The ethical committee concluded that the study did not meet the criteria for studies that require application to or approval from any ethical committee. Signed informed consent was obtained from owners of all horses included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication:"}},{"value":"CE is pharmacological advisor to Svensk Travsport (Swedish Trotting Association).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}